Roivant Sciences Ltd. Reports Financial Results for Q4 2025

Roivant Sciences Ltd., a biotech company specializing in transformative medicines across therapeutic areas such as immunology, oncology, hematology, and dermatology, has released its financial results for the fourth quarter and fiscal year ended March 31, 2025. The company, based in New York and traded on the Nasdaq, reported earnings per share (EPS) that missed analysts’ expectations by $0.03, with a GAAP EPS of -$0.29, falling short by $0.07. Revenue for the quarter was reported at $7.57 million, which was below expectations.

Despite the earnings miss, Roivant Sciences reported a significant revenue increase of 86.90% compared to the same quarter in the previous year. Analysts had anticipated a revenue of $54.1 million, indicating a discrepancy between expectations and actual performance. The company’s stock closed at $10.62 on May 27, 2025, with a 52-week high of $13.055 and a low of $8.73. The market capitalization stands at $7.81 billion, with a price-to-earnings ratio of -16.77.

H.C. Wainwright, a financial analyst firm, maintains a target price of $18 for Roivant Sciences stock, suggesting a potential upside from the current levels. The broader Nasdaq Composite index showed resilience, trading 0.50% higher at 19,195.65 points during the day, despite the earnings miss.

Roivant Sciences continues to focus on its mission to revolutionize healthcare by developing innovative solutions to pressing medical issues. The company’s performance in the recent quarter reflects both challenges and growth opportunities as it navigates the competitive biotech landscape. For more detailed insights and updates, stakeholders are encouraged to visit Roivant’s official website at www.roivant.com .